Lab managers seeking to enhance their lab’s diagnostic capabilities can now look to Azenta, Inc.’s newly launched long-read Whole Genome Sequencing (WGS) test. As the first to receive regulatory approval in the US, this test offers unparalleled accuracy in identifying genetic variations critical to understanding rare diseases.
A leap forward in diagnostic precision
Traditional sequencing methods often fall short in analyzing repetitive genomic regions where many rare diseases originate. Azenta's WGS test, powered by PacBio's Revio sequencer, overcomes these limitations by producing long and highly accurate HiFi reads, enabling detection of previously inaccessible genetic alterations.
Optimized for clinical applications
Conducted in a CLIA-certified and CAP-accredited lab, Azenta's test ensures the highest standards in clinical-grade sequencing. Its precision aids not only in diagnostics but also in developing targeted treatments and supporting clinical trials.
Benefits for lab managers:
- Enhanced Diagnostic Accuracy: Long-read technology uncovers complex genomic variations with unprecedented clarity.
- Reliable Clinical Standards: Conducted in accredited facilities, ensuring compliance and quality.
- Research Versatility: Ideal for rare disease studies, precision medicine, and translational research.
- Improved Treatment Outcomes: Provides actionable insights for targeted therapies.
- Cutting-Edge Technology: Positions your lab as a leader in genomic innovation.
With Azenta’s long-read WGS test, lab managers have an opportunity to adopt a cutting-edge technology that reshapes diagnostics and research. Its ability to deliver detailed genomic insights ensures your lab stays ahead in precision medicine advancements.
This article is an AI generated summary of a published press release "Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test"
